Dogs 6 to 20 weeks of age

Applies to:

  • Dogs presented for initial vaccination that:
    • Are late in starting the initial series 
    • Experience an extended interval (>6 wk) between doses during the initial series.

Click on a vaccine below for the recommendations:

/

CDV + CPV + CAV ± CPiV

Late starting the initial Series

Administer at least 2 sequential doses, 3 to 4 wk apart, until 16 to 20 wk of age to complete the initial series.

A noncore vaccine when administered in combination with core vaccines requires 2 doses in the absence of Maternally Derived Antibody to immunize.

(applies to both MLV and recombinant CDV vaccines)

>6 Weeks Interval Between Doses*

Administer sequential doses, 3 to 4 wk apart, with the last dose given at 16 or 20 wk of age.

A noncore vaccine when administered in combination with core vaccines requires 2 doses in the absence of Maternally Derived Antibody to immunize.

(Applies to both MLV and recombinant CDV vaccines)

* The recommended MAXIMUM interval between doses (during the initial series) is 6 wk. Dogs exceeding 6 wk between doses during the initial series should complete the initial series in accordance with recommendations outlined in this column. 

Rabies

Late starting the initial Series

Administer a single dose (not earlier than 12 wk of age).

Regardless of the dog’s age at the time the initial rabies vaccine dose is administered, a booster dose should be administered within 1 yr. (State/local/provincial statutes apply)

NOTE: Some states specify a defined time during which the second dose of rabies vaccine must be administered.)

>6 Weeks Interval Between Doses

Not Applicable

Bordetella bronchiseptica ± CPiV ± CAV (intranasal)

Late starting the initial Series

Administer a single dose at presentation.

>6 Weeks Interval Between Doses*

Administer a single dose at presentation

* The recommended MAXIMUM interval between doses (during the initial series) is 6 wk. Dogs exceeding 6 wk between doses during the initial series should complete the initial series in accordance with recommendations outlined in this column. 

 

Bordetella bronchiseptica (oral)

Late starting the initial Series

Administer a single dose at presentation.

>6 Weeks Interval Between Doses*

Administer a single dose at presentation.

* The recommended MAXIMUM interval between doses (during the initial series) is 6 wk. Dogs exceeding 6 wk between doses during the initial series should complete the initial series in accordance with recommendations outlined in this column. 

Bordetella bronchiseptica (parenteral)

Late starting the initial Series

Administer 2 doses 3 to 4 wk apart.

(NOTE: 2 consecutive doses are required to immunize.)

>6 Weeks Interval Between Doses

Published studies are not available. It is generally recommended to restart the 2-dose series when the vaccination interval between the first and second dose exceeds 6 wk.

Leptospira

Late starting the initial Series

Administer 2 doses 3 to 4 wk apart.

(NOTE: 2 consecutive doses are required to immunize.)

>6 Weeks Interval Between Doses

Published studies are not available. It is generally recommended to restart the 2-dose series when the vaccination interval between the first and second dose exceeds 6 wk.

Borrelia burgdorferi

Late starting the initial Series

Administer 2 doses 3 to 4 wk apart.

(NOTE: 2 consecutive doses are required to immunize.)

>6 Weeks Interval Between Doses

Published studies are not available. It is generally recommended to restart the 2-dose series when the vaccination interval between the first and second dose exceeds 6 wk.

Abbreviations

+ = “combined with” the vaccine that follows.
± = “with or without” the vaccine(s) that follow.
* The recommended MAXIMUM interval between doses (during the initial series) is 6 wk. Dogs exceeding 6 wk between doses during the initial series should complete the initial series in accordance with recommendations outlined in this column. 
CAV, canine adenovirus-2;
CDV, canine distemper virus;
CPiV, canine parainfluenza virus;
CPV, canine parvovirus;
MLV, modified-live virus or attenuated.

These guidelines are supported by a generous educational grant from
Boehringer Ingelheim USA Inc., Merck Animal Health, and Zoetis.